BioCentury
ARTICLE | Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

June 16, 2017 5:09 AM UTC

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of a Phase I/II trial showing that oral ASN002 was well tolerated. Pneumonia was reported as a dose-limiting toxicity (DLT) at the twice-daily 100 mg dose of ASN002. The recommended Phase II dose is twice-daily 75 mg ASN002.

Additionally, ASN002 led to 3 cases of stable disease in 1 patient each with peritoneal/ovarian cancer, neuroendocrine pancreatic cancer and peripheral T cell lymphoma (PTCL). ASN002 also led to a 43% regression of lymph nodes in a follicular lymphoma patient who received 6 prior lines of therapy. Patients received once-daily 80 or 120 mg ASN002 or twice-daily 10, 20, 30, 40, 50, 75 or 100 mg ASN002. Data were presented at the American Society of Clinical Oncology meeting in Chicago...